Cerulean Pharma Inc.

CAMBRIDGE, Mass., April 4, 2013 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that researchers will present both pre-clinical and clinical data on Cerulean's Phase 2 candidate, CRLX101, in sessions at the American Association for Cancer Research (AACR) Annual Meeting. Among the findings, Cerulean will ... read more

CAMBRIDGE, Mass., March 22, 2013 /PRNewswire/ -- Cerulean Pharma Inc. today announced that a randomized Phase 2b study of its experimental cancer treatment, CRLX101, in patients with advanced non-small cell lung cancer (NSCLC) did not meet its primary efficacy endpoint, overall survival benefit. Consistent with earlier clinical ... read more

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized ... read more

Cerulean Pharma Inc., a leader in designing and developing dynamically tumor-targeted nanopharmaceuticals, today announced that Scott D. Eliasof, Ph.D, vice president of ... read more

CAMBRIDGE, Mass, Jan. 7, 2013 /PRNewswire/ -- Cerulean Pharma Inc., a leader in designing and developing dynamically tumor-targeted nanopharmaceuticals, today announced that CRLX101 has achieved the pre-defined gating criterion for advancement into stage two of a Phase 2 clinical trial in advanced ... read more

CAMBRIDGE, Mass., Jan. 3, 2013 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in patients with advanced gastric cancer. With the 150-patient randomized Phase 2 ... read more